Fifty-four percent of adults with acute lymphoblastic leukemia (ALL) who entered the LALA-94 trial experienced a first relapse. We examined the outcome of these 421 adult patients. One hundred and eighty-seven patients (44%) achieved a second complete remission (CR). The median disease-free survival (DFS) was 5.2 months with a 5-year DFS at 12%. Factors predicting a better outcome after relapse were any transplant performed in second CR (Po0.0001), a first CR duration 41 year (P ¼ 0.04) and platelet level 4100 Â 10 9 /l at relapse (P ¼ 0.04). Risk groups defined at diagnosis and treatment received in first CR did not influence the outcome after relapse. The best results were obtained in a subset of patients who were eligible for allogeneic stem cell transplantation (SCT). Genoidentical allogeneic SCT was performed in 55 patients, and 3 patients received donor lymphocyte infusions. Forty-four transplantations were performed from an unrelated donor (of which four were cord blood). We conclude that most adult patients with recurring ALL could not be rescued using current available therapies, although allogeneic SCT remains the best therapeutic option.
Introduction
Over the last two decades, clinical trials have demonstrated an improved response rate in adult acute lymphoblastic leukemia (ALL). Advances in understanding disease biology, improvements in induction and maintenance programs using riskadapted strategies similar to treatment in children and better supportive care have all contributed. Both single institutions and multicenter studies have shown that aggressive induction plus more potent intensification programs with chemotherapy alone or chemotherapy plus stem cell transplantation (SCT) may improve treatment results. [1] [2] [3] [4] [5] [6] Although the complete remission (CR) proportions range from 60 to 90%, the long-term DFS rates are disappointingly short. 7 Leukemic relapse in adult ALL remains a major therapeutic problem. Results are unsatisfying and ALL in relapse is still regarded as an almost incurable disease. Although a second CR can be achieved, the median disease-free survival (DFS) is only 2-7.5 months. [8] [9] [10] [11] It is generally accepted that no cure can be achieved at this stage using chemotherapy alone. The only curative approach is allogeneic SCT. In general, this requires achievement of a second CR with a rescue regimen that must be effective and with as little associated toxicity as possible.
Between September 1994 and April 2004, 421 out of 771 adult patients with ALL who were included in the multicenter regimen LALA-94 trial and achieved CR experienced a primary relapse. These cases were studied with the aim to assess the following: (i) the efficacy of re-induction therapy according to risk groups defined in front-line therapy; (ii) an evaluation of post-remission strategies after achievement of a second CR and (iii) an evaluation of the utility of allogeneic SCT in the setting of a second-line therapy.
Patients and methods

Patients and first-line therapy (LALA-94 trial)
LALA-94 trial schedule has been previously detailed. 12, 13 Eligibility criteria included age 15-55 years, untreated ALL (excluding mature B-cell ALL). All patients were registered through a randomization for induction therapy. Subsequent randomizations occurred after the patients had achieved CR and were ready to start post-remission therapy ( Figure 1 ). The study was approved by the Ethics Committee (Lyon, France). All patients gave signed informed consent. The induction course was administered over a 4-week period and consisted of prednisone, vincristine, cyclophosphamide and daunorubicin or idarubicin according to initial randomization.
After induction therapy, patients followed post-induction schedules according to different risk groups. Group 1 (standard-risk ALL) comprised all T-cell lineage ALL patients achieving CR after one course of chemotherapy and B-cell lineage ALL patients defined by the absence of central nervous system-positive (CNS þ ) ALL, the absence of Philadelphia chromosome (Ph þ ), t(4;11), t(1;19), or other abnormalities involving 11q23 rearrangements, a white blood cell (WBC) count o30 Â 10 9 /l, an immunophenotype characterized by
þ and the absence of myeloid markers, and achievement of CR after one course of chemotherapy. Group 2 (high-risk ALL) was defined as nonstandard-risk ALL without Ph þ or CNS involvement. Group 3 comprised Ph þ and/or BCR-ABL þ ALL. Group 4 included all patients with evidence of CNS leukemia at diagnosis.
Standard-risk ALL patients (group 1) were randomized on day 35 and received either an intensive consolidation chemotherapy combining mitoxantrone with intermediate-dose cytarabine or a less-intensive consolidation course combining cyclophosphamide with cytarabine and 6-mercaptopurine. Then, standardrisk ALL followed a chemotherapy program over 2 years. 12 On day 35, groups 2-4 were scheduled to receive a second course of intensive chemotherapy (consolidation or salvage), consisting of mitoxantrone and intermediate-dose cytarabine. Patients who did not reach a CR after that course were withdrawn from the protocol. Based on an intention-to-treat principle, all patients in groups 3 and 4 were distributed in one of the two following SCT groups: (i) matched related allogeneic bone marrow SCT if they had a sibling donor; (ii) autologous peripheral blood SCT if they did not meet criteria for the first group. In group 2, patients without a sibling donor were randomized between the chemotherapy program and the autologous peripheral blood SCT. 12 
Biological characteristics
The morphologic diagnosis was based on May-Grü nwaldGiemsa and cytochemical staining of bone marrow smears, and was classified according to the French-American-British (FAB) classification.
14 Immunophenotyping was performed at the time of initial diagnosis, by indirect immunofluorescence using flow cytometry, focusing on the blast cell population. 12 Cytogenetic examination was also performed only at the time of initial diagnosis on bone marrow and/or blood samples. Chromosomal abnormalities were classified according to structural and numerical changes. The presence of t(4;11), t(9;22) or t(1;19) chromosomal translocations was assessed by conventional cytogenetics, and their respective gene rearrangements MLL-AF4, BCR-ABL or E2A-PBX1 were assessed by reverse transcriptase polymerase chain reaction.
Rescue therapy after primary relapse
Relapse occurring up to 1 year after CR of front-line treatment was defined as early relapse, otherwise as late relapse. In patients receiving only chemotherapy as first-line treatment, relapse occurring up to 2 years after first CR achievement was defined as 'relapse on therapy', otherwise as 'relapse off therapy', because the duration of therapy was set to be 24 months from the point of initiation of consolidation therapy. An isolated bone marrow relapse was diagnosed with X20% lymphoblasts among nucleated cells in the bone marrow and without evidence of leukemia at extramedullary sites. In patients with proven leukemia at extramedullary sites, a combined relapse was diagnosed with marrow involvement of X5% lymphoblasts. Accordingly, isolated extramedullary relapses were those with clinically overt extramedullary manifestation of leukemia and less than 5% marrow infiltration. CNS relapse was diagnosed in case of at least five leucocytes per microliter of cerebrospinal fluid and the unequivocal presence of lymphoblasts. Involvement of any other extramedullary site was confirmed histologically.
The type of combination chemotherapy program used in the salvage setting was the investigator's choice according to the initial induction and consolidation regimen, the duration of first remission, the disease features at relapse and the availability of a suitable allogeneic donor. Forty-eight patients with poor general condition at relapse only received symptomatic therapy or died early before any chemotherapy was given. All other patients were given induction therapy with various salvage induction regimens. The remission induction components can be grouped as follows: (i) vincristine/steroids-based; 6, 15 (ii) asparaginase-based; [16] [17] [18] (iii) cytarabine-based (combined with mitoxantrone, 12, 19 anthracycline, 20 fludarabine 21 or amsacrine 22, 23 ); (iv) ifosfamide-based; 24 (v) a four-drug 4-week induction similar to that of the initial induction; 12 
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Preparative regimens consisted, in most patients, of standard myeloablation using a combination of cyclophosphamide7 etoposide with either busulfan or total body irradiation. Cyclophosphamide was given as 60 mg/kg/day intravenously (i.v.) on two consecutive days; etoposide as 30-45 mg/kg i.v.; busulfan as a total of 12-16 mg/kg per os (p.o.) or equivalent i.v. dose (1 mg p.o. ¼ 0.8 mg i.v.) over four consecutive days and TBI as 12 Gy in fractionated doses over 3 days. Patients allografted from an unrelated donor received pre-transplant immunosuppression with antithymocyte globulin (2.5 mg/kg for 4 days). All patients received standard post-transplant immunosuppression comprising short-course methotrexate and cyclosporine-A that could be combined with immunoglobulins, mycophenolate mofetil or corticosteroids.
Criteria for response and relapse
Morphologic response was evaluated after re-induction therapy. Response was classified as CR or failure, including resistant disease and early death. Patients were considered to be in CR when the neutrophil count was 41.5 Â 10 9 /l, the platelet count was 4150 Â 10 9 /l, the bone marrow examination was normal and all extramedullary disease had resolved.
Relapse was defined as the reappearance of leukemic cells in the bone marrow and/or clinical evidence of disease.
Statistical analyses
Associations between pretreatment characteristics and response to induction were evaluated by the Pearson w 2 test. All tests were two-sided with statistical significance set at 0.05. Overall survival (OS) was defined as the time from relapse to death or till the last contact with the patient. DFS was defined from date of second CR to date of second relapse or death, or last contact with patient in continuous CR. DFS and OS distributions were estimated by the method of Kaplan and Meier. All treatment and subgroup comparisons were performed by the log-rank test. Simultaneous effects of multiple covariates were estimated with the maximum-likelihood logistic regression model for response and with the Cox model for DFS and OS and tested by the likelihood-ratio test, also used in univariate analyses for continuous variables. Estimated hazard ratios are reported as relative risks (RR) with 95% confidence intervals (CI). Cumulative incidence of relapse (RI) and transplant-related mortality (TRM) were calculated as described previously. 25 For patients receiving allogeneic SCT, DFS, OS, RI and TRM were calculated from time of transplantation. All computations were made using BMDP software (BMDP Statistical Software, Los Angeles, CA, USA).
Results
Pretreatment characteristics
Between September 1994 and April 2004, 421 patients with primary relapse initially enrolled into the LALA-94 trial were registered (median time to relapse, 11.4 months; range, 1.4-78.7 months). Characteristics are summarized in Table 1 . Median age at relapse was 34 years. Male/female ratio was 1.9. Immunophenotype was available at the time of initial Table 1 Clinical and biologic characteristics of the 421 relapsing patients according to risk groups defined in front-line therapy 
Outcome after relapse
Except for 48 patients who died early before any chemotherapy could be given, all other patients were given re-induction therapy with various salvage chemotherapy regimens (355 patients), autologous SCT (3 patients) with stem cells harvested at time of first CR, donor lymphocyte infusions (1 patient) or allogeneic SCT (14 patients) from a geno-identical (8 patients) or a pheno-identical (6 patients) donor. The outcome of induction therapy by salvage regimen and by risk group defined at the time of front-line therapy is summarized in Table 2 . Overall, 187 out of 421 patients (44%) achieved CR. Seventeen patients achieved a second CR with the same regimen used for induction therapy with their initial presentation. The CR proportion was 49% for patients with initial CR duration over 1 year, while it was 41% for those with a first CR duration of less than 1 year.
CR proportions among the different re-induction regimens used are indicated in Table 2 . Almost all patients (13/14 patients) undergoing salvage allogeneic SCT with active disease achieved CR. Five relapsed after a median of 14.6 months post transplant (3.8-19.8 months), and 8 patients died of transplant-related causes. After autologous SCT with active disease, 2/3 patients achieved CR. Both relapsed: one after 3 months and one after 6.4 months of the second CR duration. OS was short (median 12.5 months; range 3.7-16 months). CR was achieved in 67/123 patients (54%) with T-lineage ALL, and in 116/287 patients (40%) with (non-Ph þ ) B-lineage ALL (P ¼ 0.09). Post-remission treatments are indicated in Figure 1 . With a median follow-up from relapse of 4.3 years, the median OS was 6.3 months (Figure 2a ). Median DFS was 5.2 months with 2-year DFS at 15% and 5-year DFS at 12%. The estimated 2-year and 5-year DFS rates were 11 and 11%, and 18 and 14% for T-and (non-Ph þ ) B-lineage ALL, respectively. Outcomes according to risk groups defined at time of front-line therapy are given in Table 1 and Figure 2b .
Prognostic factors after relapse
Several factors were statistically significant as prognostic factors for outcome following relapse. In univariate analysis, male gender (49 vs 35%; P ¼ 0.008), WBC count o10 Â 10 9 /l (55 vs 34%; P ¼ 0.0002), peripheral blood blast cell count o1 Â 10 9 /l (63 vs 36%; Po0.0001), and platelet level 4100 Â 10 9 /l (59 vs 40%; P ¼ 0.005) at the time of relapse were favorable prognostic factors for achieving a CR after re-induction therapy. In logistic regression analysis, gender (RR: 0.53, 95% CI: 0.33-0.86; Table 2 Results of re-induction chemotherapy according to risk groups defined in front-line therapy and type of salvage treatment Initial postremission therapy received (chemotherapy, allogeneic SCT or autologous SCT) was not prognostic for outcome after relapse (Figure 2c ).
Feasibility and efficacy of allogeneic stem cell transplantation after relapse
We were interested to examine the role of allogeneic SCT, since this is typically regarded as the only potentially curative therapeutic option and the main goal of treatment after relapse. One hundred and twenty of the 421 relapsed patients (28%) had a potential sibling donor identified at the time of relapse. Overall allogeneic SCT or DLI infusions from a sibling donor could be performed in 58 of the relapsing patients (48%). Among the 301 relapsing patients missing a sibling donor, 44 (15%) could be transplanted from a matched unrelated donor (MUD) (10/10 or with one mismatch) (40 patients) or from cord blood (4 patients).
Sixty-one patients received allogeneic SCT (33 from a relatedidentical donor, 27 from MUD, and 1 from cord blood) as consolidation performed after achieving a second CR (median time to transplant: 1.6 months). Fourteen patients underwent allogeneic SCT while in active disease (eight from relatedidentical donor, and six from MUD) directly as salvage therapy after relapse. Twenty-four patients also received allogeneic SCT while in active disease (14 from a related-identical donor, 7 from MUD, and 3 from cord blood), but after failure of salvage chemotherapy.
Median OS from transplantation was 6.7 months with 5-year OS of 25%. OS from transplantation, TRM and RI, according to the hematologic condition in which allogeneic SCT was performed, are given in Figure 3 (b-d) showing a significantly higher survival rate at 3 years after SCT in second CR as compared to that of SCT at time of relapse (P ¼ 0.02) or to that of SCT with active disease after failure of re-induction chemotherapy (P ¼ 0.005). When comparing allogeneic SCT from MUD and allogeneic SCT from related-identical donor, survival from transplantation tended to be better (although not significantly) with MUD (3-year OS: 31 vs 21%) (Figure 3a) , in relationship with a lower RI (3-year RI: 41 vs 64%) while TRM was a little higher (TRM at 100 days: 35 vs 19%, and 1-year TRM: 46 vs 37%).
Seventeen patients had already received a transplant as part of their first-line therapy. Median survival after second allogeneic SCT was 9.3 and 44.8 months for the seven patients still alive at time of analysis.
Transplants from cord blood cells were of poor outcome with a median survival of 2.6 months (1.3-26.5 months). The two patients with active disease who received DLI died at 6.8 and 14.7 months respectively, as well as the one who received DLI after CR achievement (OS: 5.1 months).
Discussion
Our data demonstrate that the prognosis of recurrent ALL in adult patients is globally dismal. Although all patients had received similar first-line therapy, re-induction regimens were highly heterogeneous. Salvage treatment was left to the physician's choice, and was generally chosen according to the Outcome of relapsed adult ALL E Tavernier et al duration of first CR, disease features at relapse and the availability of a potential allogeneic donor. First relapse was therefore managed either by combination chemotherapy, which may be similar to the induction regimen used for front-line therapy, a first or second SCT or DLI in patients having benefited from allogeneic transplant as first-line consolidation. Less than half of our patients achieved a second CR and few were considered for allogeneic SCT, which was regarded as the treatment of choice at this stage of the disease. Because of treatment heterogeneity, it was impossible, as reported previously, 11 to determine which re-induction regimens should be recommended in recurring patients. Of note, CR was achieved in 63% of the patients who received the same four-drug 4-week induction chemotherapy than that administered in first line. Patients receiving this regimen were, however, strongly selected among patients experiencing a long first CR duration.
Prognostic factors reported in ALL at relapse have generally been similar to those reported for ALL at diagnosis. However, the prognosis seems to be driven more by the biology of the disease rather than by clinical features. [27] [28] [29] In our study, a long duration of first remission, a conserved platelet level at the time of relapse and transplantation of any type in second-line therapy were associated with better outcome. Although no satisfying explanation could be given, gender also appeared to be of prognostic value in terms of achievement of CR. 30 Our data confirm that initial therapy of adult ALL did not affect the outcome after relapse. 30 After relapse, patients had similar outcome whether they had received chemotherapy alone or with transplantation as part of their initial therapy. The risk category defined at the time of initial diagnosis also did not influence outcome after relapse. However, in contrast to what was observed in first-line therapy, 12 ALL with CNS involvement carried a particularly poor prognosis after a first relapse. Patients presenting with only CNS involvement and receiving only intrathecal chemotherapy and/or cranial irradiation had a very poor outcome, 4, 31 suggesting that systemic chemotherapy should be associated in these patients. In contrast, the outcome of Ph þ ALL after first relapse was comparable to that observed in the other ALL subtypes. These results could be explained by the recent introduction of imatinib mesylate in this subgroup of patients, and by the particularly poor outcome of all recurring ALL irrespective of their immunophenotypic characteristics.
Although allogeneic SCT then remained the only therapeutic option with curative potential, the long-term benefits of this procedure and the conditions of its application as part of the second-line therapy still remained controversial. In our experience, the 5-year survival after allogeneic SCT could be estimated at 25%. These results were in accordance with those previously reported showing long-term DFS in 15-40% of adult ALL patients after a first relapse. 11 However, most series report a longer DFS in patients who are transplanted after achievement of CR rather than with active relapse. 32, 33 This was confirmed in our study with a 5-year survival estimation of 33% after Figure 3 Allogeneic SCT in adult ALL after a first relapse: Comparison of geno-identical (55 patients) and pheno-identical SCT (40 patients) (cord blood transplants excluded) (a), Overall survival (b), of treatment-related mortality (c), relapse incidence; (d) of patients allografted after achieving a second CR (61 patients), patients who proceeded directly to allogeneic SCT after first relapse (14 patients) and patients allografted in actively relapse after failure of re-induction chemotherapy (24 patients). ALL, acute lymphoblastic leukemia; CR, complete remission; SCT, stem cell transplantation.
Outcome of relapsed adult ALL E Tavernier et al transplantation in second CR versus only 8% for those performed with active relapse. However, relapsing patients frequently have a short second remission, leaving only a brief window of time to perform SCT, and the outcome reported after allogeneic SCT in active relapse ALL appeared better in other series with long-term DFS rates ranging from 12 to 43%. 11 The outcome with allogeneic SCT is influenced by the duration of first CR, age, tumor burden and disease biology. When no sibling donor is available, identifying an unrelated donor in a timely fashion can be difficult. 34 The median time from patient referral to donor identification is about 10 weeks and 19% of referred patients died before transplantation despite all efforts to expedite SCT. 34 In our series, 46% of relapsing patients not allografted in first-line therapy with a potential sibling donor underwent SCT for second-line treatment. Twenty-nine out of the 124 patients (23%) without sibling donor, not allografted in first-line therapy and who achieved a second CR, were allografted with an unrelated donor. Using alternative donor sources such as cord blood-derived stem cells may also increase the number of potential donors. 35, 36 A second allogeneic SCT has induced leukemia-free survival rates of 10-40%, albeit with significant treatment-related mortality. 11 In our series, 17 patients received a second transplantation and 41% were still alive at the time of analysis.
In summary, our data highlight the need for therapeutic regimens specifically designed for relapsing patients, including prospective studies involving novel therapeutic agents. Our data also point out the difficulties to organize allogeneic SCT in second CR. Only a fraction of the total population benefits from a transplant after a first relapse and further efforts must be developed to speed the process of donor selection, including the identification of potential unrelated donors at the time of initial disease presentation rather than at relapse. Prevention of recurrence should also be developed. Although the role of allogeneic SCT in first-line therapy still remains controversial, [37] [38] [39] a strategy reserving allogeneic SCT as a post-relapse option does not seem to be the best therapeutic approach for most adults. The benefit of transplantation performed in first-line therapy has recently been shown in adult ALL, 12, 13, [40] [41] [42] and has been confirmed in a meta-analysis. 43 
